SEC EDGAR: Internal Investigations

Jasper Therapeutics Internal Investigation - No Drug Product Issues

Jasper Therapeutics filed an SEC Form 8-K exhibit disclosing completion of an internal investigation into anomalous clinical response data from the July 2025 BEACON study cohorts 8 and 9. The investigation confirmed no issues with the drug product (briquilimab), and a key opinion leader panel recommended enhanced site selection and patient screening criteria for future studies.

Weis Markets, Inc. - Non-Reliance on Previously Issued Financial Statements

Weis Markets, Inc. announced that its Audit Committee, in consultation with management and RSM US LLP, concluded that previously issued financial statements for fiscal years ending December 28, 2024, December 30, 2023, December 31, 2022, and interim periods in 2025 should no longer be relied upon. This conclusion impacts the company's 2024 Form 10-K and Q1-Q3 2025 Form 10-Qs.